News site default image

FDA permits marketing of AI-based device to detect certain diabetes-related eye problems

Shared by Radhika Narayanan | 0 0 0 | about 11 months ago

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.Diabetic retinopathy occurs when high levels of blood sugar lead to damage in the blood vessels of the retina, the light-sensitive tissue in the back of the eye. Diabetic retinopathy is the most common cause of vision loss among the more than 30 million Americans living with diabetes and the leading cause of vision impairment and blindness among working-age adults.Early detection of retinopathy is an important part of managing care for the millions of people with diabetes, yet many patients with diabetes are not adequately screened for diabetic retinopathy since about 50 percent of them do not see their eye doctor on a yearly basis, said Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at the FDA’s Center for Devices and Radiological Health. Todays decision permits the marketing of a novel artificial intelligence technology that can be used in a primary care doctors office. The FDA will continue to facilitate the availability of safe and effective digital health devices that may improve patient access to needed health care.

Read More On www.fda.gov

Categories Artificial intelligence & Robotics FDA

Related Post



Organizations mentioned in this article

Disease mentioned in this article

1 Votes

You must log in to post a comment